Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lytic Cycle of Bacteriophages01:30

Lytic Cycle of Bacteriophages

70.1K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
70.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

282
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
282
Inhaled Medications01:23

Inhaled Medications

210
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
210
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

159
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
159

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In situ characterization of aerosol deposition in dry powder inhalers using optical coherence tomography.

International journal of pharmaceutics·2026
Same author

Integrating single-cell RNA sequencing with multi-omics to decode disease microenvironments.

Molecular biology reports·2026
Same author

Triboelectric effect on the adhesive coating of particles in a high shear mixer.

International journal of pharmaceutics·2026
Same author

A glimpse into the future of model-informed drug discovery and development.

Advanced drug delivery reviews·2026
Same author

Recent Advances in Particle Design for High-Concentration Protein Suspension Injectables.

Pharmaceutics·2026
Same author

The Gut-Lung Axis, Epigenetics and Respiratory Disease.

Frontiers in bioscience (Landmark edition)·2026

Related Experiment Video

Updated: May 21, 2025

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.6K

Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections.

Vaibhav Pathak1, Hak-Kim Chan2, Qi Tony Zhou1

  • 1Department of Industrial and Molecular Pharmaceutics, College of Pharmacy, Purdue University, USA.

Kona : Powder Science and Technology in Japan
|March 21, 2025
PubMed
Summary

Bacteriophages (phages) offer a promising alternative to antibiotics for treating resistant lung infections. This review explores phage dry powder formulations for effective lung delivery, focusing on factors preserving phage viability.

Keywords:
antimicrobial resistancebacteriophage therapydry powder inhalerspulmonary infection

More Related Videos

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

10.7K
Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

6.4K

Related Experiment Videos

Last Updated: May 21, 2025

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.6K
P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

10.7K
Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

6.4K

Area of Science:

  • Microbiology and Virology
  • Pharmaceutical Sciences
  • Pulmonary Medicine

Background:

  • Rising antibiotic resistance necessitates novel antimicrobial strategies.
  • Bacteriophages (phages) are specific bacterial viruses with therapeutic potential.
  • Pulmonary infections often involve multidrug-resistant pathogens.

Purpose of the Study:

  • To review recent advancements in bacteriophage dry powder formulations.
  • To investigate the impact of excipients and manufacturing on phage titer preservation.
  • To highlight the potential of dry powder inhalers for phage lung delivery.

Main Methods:

  • Literature review of studies on bacteriophage dry powder formulations.
  • Analysis of factors affecting phage stability in dry powder form.
  • Evaluation of dry powder inhaler technology for pulmonary phage delivery.

Main Results:

  • Dry powder inhalers offer advantages for lung delivery, including ease of use, portability, and stability.
  • Excipients and manufacturing processes significantly influence phage titer preservation in dry powders.
  • Specific formulation strategies can enhance phage viability for treating pulmonary infections.

Conclusions:

  • Bacteriophage dry powder formulations are a viable strategy for combating antibiotic-resistant pulmonary infections.
  • Optimizing formulation and manufacturing is crucial for successful clinical application.
  • Further research is needed to fully realize the potential of phage therapy via inhalation.